MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer

08-Jun-2017 - Belgium

MRC Technology and Biocartis Group NV announced a partnership to develop selected molecular diagnostic tests for use on Biocartis' fully automated Idylla(TM) platform. MRCT aims to move promising medical research forward into patient treatments and diagnostics and has been involved in helping deliver a number of therapies.

Under the terms of the agreement, Biocartis and MRCT will jointly develop selected molecular diagnostic tests for use on the fully automated Idylla(TM) platform. For each selected test, MRCT will act as a development contractor, whereas Biocartis will be responsible for the commercialization of the tests under its own label. Financial details of the partnership are not disclosed.

The first test to be developed under the partnership is a liquid biopsy test aimed at monitoring of metastatic breast cancer patients for resistance to hormone therapy. This is an important first step in the breast cancer menu that Biocartis is developing, and has a clear strategic fit within the Company's focus on liquid biopsy testing.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance